21 July 2025

Osteopore secures RGO clearance to rebuild jawbones at Princess Alexandra Hospital

Highlights

- **On 4 June 2025, Osteopore launched a clinical study with Princess Alexandra Hospital for maxillomandibular reconstruction in a minimum of 10 adult patients.**
- **The clinical study has now received Research Governance Office (RGO) clearance, and the first patient is expected to be recruited in 4 weeks.**

Global regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that its breakthrough clinical trial for jawbone regeneration, conducted in partnership with Princess Alexandra Hospital (PAH), has secured clearance from the Research Governance Office (RGO). The first patient is expected to be recruited in 4 weeks.

Launched on 4 June 2025, the single-arm feasibility study for maxillomandibular reconstruction seeks to recruit at least 10 adult patients in Australia by 2028. Each patient will be assessed 36 months post-surgery.

The study explores the safety and tolerability of Osteopore's cutting-edge polycaprolactone-tricalcium phosphate (PCL-TCP) scaffold, used in combination with a vascularised corticoperiosteal tissue transfer, a technique designed to regenerate maxilla and mandible bone.

The maxilla and mandible bones support basic abilities like breathing, chewing, swallowing and speaking while contributing to facial appearance and psychological well-being.

Current state-of-the-art treatments comprise autologous free tissue transfer, but this leads to complications such as donor site morbidity, limited suitability for complex defects, a shortage of donor site bone, and insufficient bone height for effective dental rehabilitation.

Commenting on obtaining RGO clearance and the expected recruitment of the first patient to the clinical study at PAH, CEO Dr Yujing Lim, said:

"We are grateful that the necessary approvals have been obtained and that the first patient will soon be recruited to the study.

"The loss of substantial jawbone is a particularly debilitating condition, and through this study, we hope that the safety and tolerability of our proposed solution may be demonstrated.

"We look forward to continued momentum in the study, which will be another step closer to making this regenerative approach to jaw healing a reality for patients globally," said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Isaac Stewart
Media & Investor Relations
Purple
E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.